Nufarm (ASX:NUF)- CEO, Greg Hunt
CEO, Greg Hunt
Source: Nufarm
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • The US Food and Drug Administration (FDA) recognises Nufarm’s (NUF) Nuseed omega-3 canola oil as a new dietary ingredient
  • The company has created a plant-based source of omega-3 fatty acids as an alternative to fish oil, the most common source of omega-3
  • According to NUF, the oil will help reduce pressure on wild-fish stocks
  • CEO Greg Hunt said FDA approval is a huge milestone for the company
  • On market close for the day, Nufarm was up 3.21 per cent and is trading at $4.50 per share

The US Food and Drug Administration (FDA) has recognised Nufarm’s (NUF) Nuseed omega-3 canola oil as a new dietary ingredient.

The company has created a plant-based source of omega-3 fatty acids and is an alternative to fish oil, the most common source of omega-3.

Omega-3 have several health benefits, such as lowering blood pressure and raising.

Nuseed’s omega-3 canola helps fill the gap between how much long-chain omega-3 is needed to support human and animal nutrition and how little the ocean can sustainably provide.

CEO Greg Hunt said FDA approval is a huge milestone for the company.

“The FDA’s acknowledgment along with our recently completed human clinical trial, allows us to progress our plans to expand into the human nutrition market and meet a growing demand for plant-based omega-3 essential oil options,” Mr Hunt said.

“With FDA recognition of Nuseed’s conclusion that Nutriterra is a safe new dietary ingredient, we are well placed to secure commercial partnerships that will attract new consumers, enter into new segments and raise consumption of omega-3.”

Notably, a human trial was conducted with the omega-3 canola oil and showed participants absorbing the oil’s omega-3s.

On market close for the day, Nufarm was up 3.21 per cent and is trading at $4.50 per share.

NUF by the numbers
More From The Market Online
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
Image of a woman holding a bottle of hemp oil

Little Green Pharma jumps into distribution with acquisition

Little Green Pharma is aiming to make the strategic acquisition of HH (Australia) Pty Ltd to…
Image of cancer cells

Radiopharm approved to start Lu-RAD202 safety trials, door open for in-human studies

Radiopharm Theranostics has received ethics approval for its trial into Lu-RAD202, a novel treatment for these…
Close up of a nasal spray

LTR Pharma pairs with Men’s Health Downunder for supply of erectile dysfunction spray

LTR Pharma Ltd has signed an agreement with Men's Health Downunder to facilitate supply of its…